Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case-control study - PubMed (original) (raw)

Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case-control study

Nayeong Son et al. BMC Cardiovasc Disord. 2022.

Abstract

Background: Recent studies have raised concern about the association of fluoroquinolones with an increased risk of aortic aneurysm and aortic dissection. We aimed to evaluate such risk in a Korean population.

Methods: We conducted a nested case-control study using data from the National Health Insurance Service collected from 2013 to 2017 in Korea. The study cohort included patients older than 40 years and excluded patients who had used fluoroquinolones or been diagnosed with aortic aneurysm, aortic dissection, or related diseases 1 year prior to the cohort entry date. We randomly matched four controls in the risk set with each case of aortic aneurysm and aortic dissection (same sex, age, and cohort entry date). We assessed the risk of aortic aneurysm and aortic dissection from fluoroquinolones and adjusted for potential confounders using a conditional logistic regression model.

Results: A total of 29,638 aortic aneurysm and aortic dissection patients were identified between 2014 and 2017. The use of fluoroquinolones within a year was associated with a 10% increased risk of aortic aneurysm and aortic dissection (adjusted odds ratio: 1.10, 95% CI 1.07-1.14, p < 0.05) compared with nonusers. The risk was higher in patients who had used fluoroquinolones within 60 days (adjusted odds ratio: 1.53, 95% CI 1.46-1.62, p < 0.05). The risk of aortic aneurysm and aortic dissection positively correlated with the cumulative dose and duration of fluoroquinolone therapy (p < 0.001).

Conclusions: Our study provides real-world evidence of the risk of aortic aneurysm and aortic dissection from fluoroquinolones in Korea. Patients and medical professionals should be aware that fluoroquinolones can increase the risk of aortic aneurysm and aortic dissection, which may be acerbated by high dosage and duration of use.

Keywords: Adverse effect; Aortic aneurysm; Aortic dissection; Drug safety; Fluoroquinolone; Pharmacovigilance.

© 2022. The Author(s).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1

Fig. 1

Results of conditional logistic regression analysis of the association between AA/AD and FQ use

Similar articles

Cited by

References

    1. Kim Y, Park Y, Youk T, Lee S, Son Y. A study on the use of antibiotics in Korea and the resistance of major pathogens to antibiotics. NHIS Ilsan hospital Report. 2016:20-001.
    1. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22(8):438–445. doi: 10.1016/j.tim.2014.04.007. - DOI - PubMed
    1. Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. doi: 10.1136/bmj.k678. - DOI - PMC - PubMed
    1. Food and Drug Administration (FDA). Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2018. https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm. Accessed 14 Jan 2022.
    1. Ministry of Food and Drug Safety (MFDS). A notification on the distribution of safety letters on fluoroquinolone antibiotics. https://www.mfds.go.kr/brd/m_545/view.do?seq=286&srchFr=&srchTo=&srchWor.... Accessed 14 Jan 2022.

MeSH terms

Substances

LinkOut - more resources